2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgery
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness
1996
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsAntibody SpecificityHumansImmunohistochemistryMaleProstatic NeoplasmsProtein Serine-Threonine KinasesRabbitsReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTumor Cells, CulturedConceptsType II receptorHuman prostate cancer tissuesProstate cancer tissuesII receptorsProstate cancer cellsLoss of expressionTumor gradeTGF-beta receptorsCancer tissuesProstate tissueTGF-beta1 type IProstate cancer cell growthMalignant human prostate tissueType ICancer cellsHuman prostate cancer cellsGrowth factor-beta type IProstate cancer casesHuman prostate cancerBenign prostate tissueCancer cell growthHuman prostate tissueTGF-beta type IGrowth factor beta1Benign human prostate